Researcher at UNISA, Baronissi
📍 Università degli Studi di Salerno — Dipartimento di Medicina, Chirurgia ed Odontoiatria
Grant received: €3.000Developing a non-invasive test based on salivary biomarkers (genetic, microbiome, immunological) to predict which lung cancer patients will develop immune-related adverse events (irAEs) before therapy begins. A precision-medicine approach combined with accessible laboratory medicine.
To advance precision oncology by implementing Immuno-SAFE, a rapid and non-invasive system predicting severe irAEs in NSCLC patients eligible for anti-PD-1/PD-L1 immunotherapy. The project aims to improve treatment personalisation, enhance patient safety, reduce avoidable hospitalisations, and support the regional and national transition toward more efficient, sustainable immunotherapy management.
Early and accurate identification of NSCLC patients at high risk of severe irAEs, enabling more personalised and safer immunotherapy pathways. Reduction of treatment interruptions, emergency admissions, and irAE-related healthcare costs. Strengthened precision oncology services across regional centres, improving clinical workflow efficiency, the sustainability of immunotherapy programmes, and overall patient outcomes.
Every €3,000 raised = one more grant in the next call. You run, you donate, they do research.
Donate now See the open call